Back to all studies
CompletedNCT03403790

A Survey on Quetiapine Extended-release Tablets in people with Depression in Bipolarity

This study is completed. It focuses on bipolarity and currently lists study information in Japan.

Bipolarity, DepressionDrug

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether surveys or interviews may be useful for people experiencing bipolarity.

What would participation involve?

Participants may answer questionnaires, join interviews, or provide follow-up information, attend study visits with the research team. The registry lists locations in Japan.

Who is it mainly for?

This study appears to be mainly for people with bipolarity.

What should you check before joining?

Ask about whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: January 15, 2018
Recruitment status
Completed
Enrollment listed in the registry
369
Sponsor
Astellas Pharma Inc
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Not clearly listed
Locations
Japan
Age range
Not clearly listed
Official registry ID
NCT03403790
Official title
Drug Use-results Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Japan · 47 sites
  • Site JP00023
    Aichi
    Site status: Not listed — confirm with the team
  • Site JP00005
    Akita
    Site status: Not listed — confirm with the team
  • Site JP00002
    Aomori
    Site status: Not listed — confirm with the team
  • Site JP00012
    Chiba
    Site status: Not listed — confirm with the team
  • Site JP00038
    Ehime
    Site status: Not listed — confirm with the team
  • Site JP00018
    Fukui
    Site status: Not listed — confirm with the team
  • Site JP00040
    Fukuoka
    Site status: Not listed — confirm with the team
  • Site JP00007
    Fukushima
    Site status: Not listed — confirm with the team
  • Site JP00021
    Gifu
    Site status: Not listed — confirm with the team
  • Site JP00010
    Gunma
    Site status: Not listed — confirm with the team
  • Site JP00034
    Hiroshima
    Site status: Not listed — confirm with the team
  • Site JP00001
    Hokkaido
    Site status: Not listed — confirm with the team
  • Site JP00028
    Hyōgo
    Site status: Not listed — confirm with the team
  • Site JP00008
    Ibaraki
    Site status: Not listed — confirm with the team
  • Site JP00017
    Ishikawa
    Site status: Not listed — confirm with the team
  • Site JP00037
    Kagawa
    Site status: Not listed — confirm with the team
  • Site JP00046
    Kagoshima
    Site status: Not listed — confirm with the team
  • Site JP00014
    Kanagawa
    Site status: Not listed — confirm with the team
  • Site JP00039
    Kochi
    Site status: Not listed — confirm with the team
  • Site JP00043
    Kumamoto
    Site status: Not listed — confirm with the team
  • Site JP00026
    Kyoto
    Site status: Not listed — confirm with the team
  • Site JP00024
    Mie
    Site status: Not listed — confirm with the team
  • Site JP00004
    Miyagi
    Site status: Not listed — confirm with the team
  • Site JP00045
    Miyazaki
    Site status: Not listed — confirm with the team
  • Site JP00020
    Nagano
    Site status: Not listed — confirm with the team
  • Site JP00042
    Nagasaki
    Site status: Not listed — confirm with the team
  • Site JP00029
    Nara
    Site status: Not listed — confirm with the team
  • Site JP00015
    Niigata
    Site status: Not listed — confirm with the team
  • Site JP00003
    Numakunai
    Site status: Not listed — confirm with the team
  • Site JP00033
    Okayama
    Site status: Not listed — confirm with the team
  • Site JP00047
    Okinawa
    Site status: Not listed — confirm with the team
  • Site JP00027
    Osaka
    Site status: Not listed — confirm with the team
  • Site JP00044
    Ōita
    Site status: Not listed — confirm with the team
  • Site JP00041
    Saga
    Site status: Not listed — confirm with the team
  • Site JP00011
    Saitama
    Site status: Not listed — confirm with the team
  • Site JP00025
    Shiga
    Site status: Not listed — confirm with the team
  • Site JP00032
    Shimane
    Site status: Not listed — confirm with the team
  • Site JP00022
    Shizuoka
    Site status: Not listed — confirm with the team
  • Site JP00009
    Tochigi
    Site status: Not listed — confirm with the team
  • Site JP00036
    Tokushima
    Site status: Not listed — confirm with the team
  • Site JP00013
    Tokyo
    Site status: Not listed — confirm with the team
  • Site JP00031
    Tottori
    Site status: Not listed — confirm with the team
  • Site JP00016
    Toyama
    Site status: Not listed — confirm with the team
  • Site JP00030
    Wakayama
    Site status: Not listed — confirm with the team
  • Site JP00006
    Yamagata
    Site status: Not listed — confirm with the team
  • Site JP00035
    Yamaguchi
    Site status: Not listed — confirm with the team
  • Site JP00019
    Yamanashi
    Site status: Not listed — confirm with the team

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT03403790. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Quetiapine. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

Who might this study be for?

This study may concern people with bipolarity. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Astellas Pharma Inc, which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me